Osteoarthritis Therapeutics Market Report and Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,999	200 Pages	Expert Market Research	September, 2023	EMAR18268775

Best Price Guarantee
Price	from $2,999
Length	200 Pages
Publisher	Expert Market Research
Published Date	September, 2023
SKU	EMAR18268775

Osteoarthritis Therapeutics Market Report and Forecast 2024-2032

Osteoarthritis Therapeutics Market Outlook

The osteoarthritis therapeutics market size was valued at USD 9.1 billion in 2023, driven by the increasing geriatric population across the globe. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 19.1 billion by 2032.

Osteoarthritis Therapeutics: Introduction

Osteoarthritis therapeutics refer to the various treatment options and approaches used to manage and alleviate the symptoms of osteoarthritis, a common degenerative joint disease characterized by the breakdown of cartilage in the joints. Osteoarthritis primarily affects the knees, hips, hands, and spine and can result in joint pain, stiffness, reduced mobility, and decreased quality of life. The choice of therapeutic interventions depends on the severity of the condition, the affected joints, and individual patient needs.

Key Trends in the Osteoarthritis Therapeutics Market

Here are some key trends influencing the market:

Biologics and Regenerative Therapies: The use of biologics, including platelet-rich plasma (PRP) and stem cell therapies, is a growing trend in osteoarthritis treatment. These therapies aim to promote tissue repair and regeneration.
Precision Medicine: Advancements in genomics and biomarker research are leading to the development of personalized treatment plans based on the patient's genetic and molecular profile, optimizing therapeutic outcomes.
Telemedicine and Remote Monitoring: Telehealth and remote monitoring solutions are increasingly used for patient consultations and follow-ups, making it more convenient for osteoarthritis patients to access care and track their progress.
Patient Education and Engagement: The availability of online resources and educational materials empowers patients to take an active role in managing their osteoarthritis. Healthcare providers are focusing on patient education and engagement to improve adherence to treatment plans.
Wearable Technology: Wearable devices, such as smart braces and activity trackers, are becoming valuable tools for monitoring joint health, tracking physical activity, and providing real-time feedback to patients.
Nutraceuticals and Supplements: The use of dietary supplements and nutraceuticals, such as glucosamine, chondroitin, and turmeric, is a growing trend among osteoarthritis patients seeking alternative or complementary therapies.

Osteoarthritis Therapeutics Market Segmentations

Market Breakup by Type

Hip Osteoarthritis
Spinal Osteoarthritis
Knee Osteoarthritis
Hand Osteoarthritis
Others

Market Breakup by Drug Class

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Analgesics
Corticosteroids
Hyaluronic Acid Injections
Disease-modifying Osteoarthritis Drugs
Others

Market Breakup by Doses Form

Tablets and Capsules
Injections
Creams and Gels
Others

Market Breakup by Route of Administration

Oral
Parenteral
Topical

Market Breakup by End User

Hospitals
Specialty Clinics
Homecare Settings
Others

Market Breakup by Distribution Channel

Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Market Breakup by Region -7MM

United States
EU-4 and the United Kingdom
Japan

Osteoarthritis Therapeutics Market Overview

Here are some market drivers impacting the market:

Aging Population: The global aging population is a significant driver of the osteoarthritis therapeutics market. As individuals age, the risk of developing osteoarthritis increases, leading to a higher demand for treatments to manage the condition.
Rising Prevalence: Osteoarthritis is one of the most common musculoskeletal disorders globally, with a rising prevalence. This increase in the number of affected individuals drives the need for effective therapeutics.
Advancements in Treatment: Ongoing research and development efforts have led to the discovery of new treatment modalities, including disease-modifying drugs and regenerative therapies, which offer potential benefits for osteoarthritis patients.
Patient-Centered Care: The shift toward patient-centered care models emphasizes personalized treatment plans tailored to individual patient needs and preferences. This trend influences treatment choices and the development of patient-friendly therapeutics.
Technological Innovations: Advancements in medical technology, such as minimally invasive surgical techniques and imaging modalities, enhance the diagnosis and treatment of osteoarthritis, driving the demand for therapeutics.
Healthcare Infrastructure Development: Investments in healthcare infrastructure, especially in emerging markets, contribute to improved access to osteoarthritis diagnosis and treatment, thereby expanding the market.

Osteoarthritis Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Pfizer Inc.
Abbvie Inc.
Novartis AG
Amgen Inc.
Boehringer Ingelheim International GmbH.
Samsung Bioepis
Merck & Co Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries Ltd.
AstraZeneca PL
Zimmer Biomet
Stryker Corporation

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Osteoarthritis Overview: 3.1 Guidelines and Stages; 3.2 Pathophysiology; 3.3 Screening and Diagnosis; 3.4 Treatment Pathway
4 Patient Profile: 4.1 Patient Profile Overview; 4.2 Patient Psychology and Emotional Impact Factors; 4.3 Risk Assessment and Treatment Success Rate
5 Osteoarthritis Epidemiology Analysis-7MM: 5.1 Epidemiology Overview (2017-2032); 5.2 United States Osteoarthritis Epidemiology (2017-2032); 5.3 EU-4 and United Kingdom Osteoarthritis Epidemiology (2017-2032); 5.4 Japan Osteoarthritis Epidemiology (2017-2032)
6 Osteoarthritis Therapeutics Market Overview: 6.1 Osteoarthritis Therapeutics Market Historical Value (2017-2023); 6.2 Osteoarthritis Therapeutics Market Forecast Value (2024-2032)
7 Osteoarthritis Therapeutics Market Landscape: 7.1 Osteoarthritis Therapeutics: Developers Landscape; 7.1.1 Analysis by Year of Establishment; 7.1.2 Analysis by Company Size; 7.1.3 Analysis by Region; 7.2 Osteoarthritis Therapeutics: Product Landscape; 7.2.1 Analysis by Therapy Type; 7.2.2 Analysis by Drug Class; 7.2.3 Analysis by Route of Administration
8 Osteoarthritis Therapeutics Challenges and Unmet Needs: 8.1 Treatment Pathway Challenges; 8.2 Compliance and Drop-Out Analysis; 8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Osteoarthritis Therapeutics Market Dynamics: 10.1 Market Drivers and Constraints; 10.2 SWOT Analysis; 10.3 Porter’s Five Forces Model; 10.4 Key Demand Indicators; 10.5 Key Price Indicators; 10.6 Industry Events, Initiatives, and Trends; 10.7 Value Chain Analysis
11 Osteoarthritis Therapeutics Market Segmentation: 11.1 Osteoarthritis Therapeutics Market by Type; 11.1.1 Market Overview; 11.1.2 Hip Osteoarthritis; 11.1.3 Spinal Osteoarthritis; 11.1.4 Knee Osteoarthritis; 11.1.5 Hand Osteoarthritis; 11.1.6 Others; 11.2 Osteoarthritis Therapeutics Market by Drug Class; 11.2.1 Market Overview; 11.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs); 11.2.3 Analgesics; 11.2.4 Corticosteroids; 11.2.5 Hyaluronic Acid Injections; 11.2.6 Disease-modifying Osteoarthritis Drugs; 11.2.7 Others; 11.3 Osteoarthritis Therapeutics Market by Doses Form; 11.3.1 Market Overview; 11.3.2 Tablets & Capsules; 11.3.3 Injections; 11.3.4 Creams and Gels; 11.3.5 Others; 11.4 Osteoarthritis Therapeutics Market by Route of Administration; 11.4.1 Market Overview; 11.4.2 Oral; 11.4.3 Parenteral; 11.4.4 Topical; 11.5 Osteoarthritis Therapeutics Market by End User; 11.5.1 Market Overview; 11.5.2 Hospitals; 11.5.3 Specialty Clinics; 11.5.4 Homecare Settings; 11.5.5 Others; 11.6 Osteoarthritis Therapeutics Market by Distribution Channel; 11.6.1 Market Overview; 11.6.2 Hospitals Pharmacy; 11.6.3 Retail Pharmacy; 11.6.4 Online Pharmacy; 11.6.5 Others; 11.7 Osteoarthritis Therapeutics Market by Region-7MM; 11.7.1 Market Overview; 11.7.2 United States; 11.7.3 EU-4 and the United Kingdom; 11.7.4 Japan
12 United States Osteoarthritis Therapeutics Market: 12.1 U.S. Osteoarthritis Therapeutics Market Historical Size (2017-2023); 12.2 U.S. Osteoarthritis Therapeutics Market Forecast Size (2024-2032); 12.3 Market Size by Drug Class
13 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market: 13.1 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Historical Size (2017-2023); 13.2 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Forecast Size (2024-2032); 13.3 Market Size by Drug Class
14 Japan Osteoarthritis Therapeutics Market: 14.1 Japan Osteoarthritis Therapeutics Market Historical Size (2017-2023); 14.2 Japan Osteoarthritis Therapeutics Market Forecast Size (2024-2032); 14.3 Market Size by Drug Class
15 Regulatory Framework: 15.1 Regulatory Overview; 15.1.1 US FDA; 15.1.2 EU EMA; 15.1.3 JAPAN PMDA
16 Patent Analysis: 16.1 Analysis by Type of Patent; 16.2 Analysis by Publication year; 16.3 Analysis by Issuing Authority; 16.4 Analysis by Patent Age; 16.5 Analysis by CPC Analysis; 16.6 Analysis by Patent Valuation; 16.7 Analysis by Key Players
17 Grants Analysis: 17.1 Analysis by year; 17.2 Analysis by Amount Awarded; 17.3 Analysis by Issuing Authority; 17.4 Analysis by Grant Application; 17.5 Analysis by Funding Institute; 17.6 Analysis by NIH Departments; 17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis: 18.1 Analysis by Trial Registration Year; 18.2 Analysis by Trial Status; 18.3 Analysis by Trial Phase; 18.4 Analysis by Therapeutic Area; 18.5 Analysis by Geography
19 Funding and Investment Analysis: 19.1 Analysis by Funding Instances; 19.2 Analysis by Type of Funding; 19.3 Analysis by Funding Amount; 19.4 Analysis by Leading Players; 19.5 Analysis by Leading Investors; 19.6 Analysis by Geography
20 Partnership and Collaborations Analysis: 20.1 Analysis by Partnership Instances; 20.2 Analysis by Type of Partnership; 20.3 Analysis by Leading Players; 20.4 Analysis by Geography
21 Supplier Landscape: 21.1 Pfizer Inc.; 21.1.1 Financial Analysis; 21.1.2 Product Portfolio; 21.1.3 Demographic Reach and Achievements; 21.1.4 Mergers and Acquisitions; 21.1.5 Certifications; 21.2 Abbive Inc.; 21.2.1 Financial Analysis; 21.2.2 Product Portfolio; 21.2.3 Demographic Reach and Achievements; 21.2.4 Mergers and Acquisitions; 21.2.5 Certifications; 21.3 Novartis AG; 21.3.1 Financial Analysis; 21.3.2 Product Portfolio; 21.3.3 Demographic Reach and Achievements; 21.3.4 Mergers and Acquisitions; 21.3.5 Certifications; 21.4 Amgen Inc.; 21.4.1 Financial Analysis; 21.4.2 Product Portfolio; 21.4.3 Demographic Reach and Achievements; 21.4.4 Mergers and Acquisitions; 21.4.5 Certifications; 21.5 Boehringer Ingelheim International GmbH.; 21.5.1 Financial Analysis; 21.5.2 Product Portfolio; 21.5.3 Demographic Reach and Achievements; 21.5.4 Mergers and Acquisitions; 21.5.5 Certifications; 21.6 F. Hoffmann-La Roche Ltd.; 21.6.1 Financial Analysis; 21.6.2 Product Portfolio; 21.6.3 Demographic Reach and Achievements; 21.6.4 Mergers and Acquisitions; 21.6.5 Certifications; 21.7 Merck & Co Inc.; 21.7.1 Financial Analysis; 21.7.2 Product Portfolio; 21.7.3 Demographic Reach and Achievements; 21.7.4 Mergers and Acquisitions; 21.7.5 Certifications; 21.8 Teva Pharmaceutical Industries Ltd.; 21.8.1 Financial Analysis; 21.8.2 Product Portfolio; 21.8.3 Demographic Reach and Achievements; 21.8.4 Mergers and Acquisitions; 21.8.5 Certifications; 21.9 Sun Pharmaceutical Industries Ltd.; 21.9.1 Financial Analysis; 21.9.2 Product Portfolio; 21.9.3 Demographic Reach and Achievements; 21.9.4 Mergers and Acquisitions; 21.9.5 Certifications; 21.10 AstraZeneca PL; 21.10.1 Financial Analysis; 21.10.2 Product Portfolio; 21.10.3 Demographic Reach and Achievements; 21.10.4 Mergers and Acquisitions; 21.10.5 Certifications; 21.11 Zimmer Biomet; 21.11.1 Financial Analysis; 21.11.2 Product Portfolio; 21.11.3 Demographic Reach and Achievements; 21.11.4 Mergers and Acquisitions; 21.11.5 Certifications; 21.12 Stryker Corporation; 21.12.1 Financial Analysis; 21.12.2 Product Portfolio; 21.12.3 Demographic Reach and Achievements; 21.12.4 Mergers and Acquisitions; 21.12.5 Certifications
22 Osteoarthritis Therapeutics - Distribution Model (Additional Insight): 22.1 Overview; 22.2 Potential Distributors; 22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight): 24.1 Very Small Companies; 24.2 Small Companies; 24.3 Mid-Sized Companies; 24.4 Large Companies; 24.5 Very Large Companies
25 Payment Methods (Additional Insight): 25.1 Government Funded; 25.2 Private Insurance; 25.3 Out-of-Pocket; *Additional insights provided are customisable as per client requirements.